BACKGROUND: Acute hypertension during cardiac surgery can be difficult to manage and may adversely affect patient outcomes. Clevidipine is a novel, rapidly acting dihydropyridine L-type calcium channel blocker with an ultrashort half-life that decreases arterial blood pressure (BP). The Evaluation of CLevidipine In the Perioperative Treatment of Hypertension Assessing Safety Events trial (ECLIPSE) was performed to compare the safety and efficacy of clevidipine (CLV) with nitroglycerin (NTG), sodium nitroprusside (SNP), and nicardipine (NIC) in the treatment of perioperative acute hypertension in patients undergoing cardiac surgery. METHODS: We analyzed data from three prospective, randomized, open-label, parallel comparison studies of CLV to NTG or SNP perioperatively, or NIC postoperatively in patients undergoing cardiac surgery at 61 medical centers. Of the 1964 patients enrolled, 1512 met postrandomization inclusion criteria of requiring acute treatment of hypertension based on clinical criteria. The patients were randomized 1:1 for each of the three parallel comparator treatment groups. The primary outcome was the incidence of death, myocardial infarction, stroke or renal dysfunction at 30 days. Adequacy and precision of BP control was evaluated and is reported as a secondary outcome. RESULTS: There was no difference in the incidence of myocardial infarction, stroke or renal dysfunction for CLV-treated patients compared with the other treatment groups. There was no difference in mortality rates between the CLV, NTG or NIC groups. Mortality was significantly higher, though, for SNP-treated patients compared with CLV-treated patients (P ϭ 0.04). CLV was more effective compared with NTG (P ϭ 0.0006) or SNP (P ϭ 0.003) in maintaining BP within the prespecified BP range. CLV was equivalent to NIC in keeping patients within a prespecified BP range; however, when BP range was narrowed, CLV was associated with fewer BP excursions beyond these BP limits compared with NIC. CONCLUSIONS: CLV is a safe and effective treatment for acute hypertension in patients undergoing cardiac surgery.
The etiology and treatment responsiveness of acute perioperative hypertension differs from chronic hypertension. Acute perioperative hypertension may be transient and is characterized by excessive catecholamine release, peripheral vasoconstriction, 12 and reduced baroreceptor sensitivity. 13 Acute hypertension has been reported to worsen reperfusion injury, 14 humoral and cellular inflammatory response, 15, 16 and platelet activation 17 which may compromise microvascular blood flow. In addition, perioperative hypertension increases myocardial oxygen consumption and left ventricular end-diastolic pressure, and contributes to subendocardial hypoperfusion and myocardial ischemia. 1, 6, 18 Despite its frequency and potential morbidity, there are no established guidelines for treating acute hypertension in the perioperative patient population and there is significant practice variability. 19 The ideal drug for the management of hypertension in cardiac surgical patients would be a short-acting parenteral drug that is easily and rapidly titratable. Commonly used drugs include sodium nitroprusside, nitroglycerin, ␤ blockers, and calcium channel blockers, as well as volatile anesthetics and sedatives. All of these drugs have limitations related to their potency, tolerance, toxicity, side effects, applicability, onset and offset of action, and ease of use. Clevidipine is a rapid-acting, dihydropyridine L-type calcium channel antagonist with an ultrashort half-life of approximately one min 20 -23 that decreases arterial pressure by direct arterial vasodilation. It has selective action on arteriolar resistance vessels with no effect on venous capacitance vessels. Reflex tachycardia and tachyphylaxis have not been reported.
The primary objective of this study was to compare the safety of clevidipine to three commonly used perioperative antihypertensive drugs (nitroglycerin, sodium nitroprusside, and nicardipine) in a cardiac surgical population. The secondary end-point of BP control was evaluated by measuring the magnitude and duration of BP excursions above or below a predefined systolic blood pressure (SBP) range.
METHODS

Study Design
The ECLIPSE (Evaluation of CLevidipine In the Perioperative Treatment of Hypertension Assessing Safety Events) trial was conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. The study was approved by the IRB at each participating institution. The three studies making up the ECLIPSE trial were performed under IND 65,114 and were registered at clinicaltrials.gov under the identifiers NCT00093886, NCT00093912, and NCT00093925. Written informed consent was obtained from all patients before enrollment. The ECLIPSE trial was randomized, open-label, prospective, and was conducted at 61 medical centers in the United States between April 2004 and October 2006.
Patients 18-yr-of-age or older and scheduled to undergo cardiac surgery (including on-or off-pump coronary artery bypass grafting [CABG] , minimally invasive CABG and/or valve replacement or repair surgery) at each participating institution were evaluated for study eligibility. Patients were excluded from study for the following reasons: women of childbearing potential, cerebrovascular accident Յ3 mo before randomization, intolerance to calcium channel blockers, hypersensitivity to sodium nitroprusside, nitroglycerin, or nicardipine, allergy to the lipid vehicle of clevidipine, permanent ventricular pacing, any condition or disease deemed by the investigator to place the patient at risk for participating, or participation in another investigation within 30 days of study start.
The ECLIPSE study consisted of three parallel trials where patients were randomly assigned on a 1:1 basis to receive clevidipine or a comparator drug (sodium nitroprusside, nitroglycerin, or nicardipine). After enrollment and treatment randomization, the need for antihypertensive treatment was determined by the study physician in accordance with department clinical practice and relevant institutional guidelines (e.g., postoperative intensive care unit guidelines).
Drug Administration
Study drug was administered IV, either peripherally or centrally, with an infusion pump. Treatment was titrated to achieve a BP level deemed appropriate by the study physician and continued until discharge from the intensive care unit. Use of nonstudy drug medications to treat hypertension during study drug administration was discouraged. If the desired BP effect was not attained or maintained with either clevidipine or a comparator drug, or if there was a safety concern, an alternative IV antihypertensive could be used per institutional practice to decrease BP. All antihypertensive medications were recorded.
Clevidipine was initiated at an infusion rate of 0.4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 and was titrated as tolerated in doubling increments every 90 s up to 3.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 . Infusion rates above 3.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 were guided by the patient's response and permitted in serial increments of 1.5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 . Infusion rates between 4.4 and 8.0 g ⅐ kg Ϫ1 ⅐ min Ϫ1 were administered for no longer than 2 h. Titration to higher infusion rates, up to the maximum infusion rate of 8.0 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , was required before switching to or adding alternative antihypertensive drugs, assuming that each dose was well tolerated by the patient and there were no safety concerns. Due to protocolspecified lipid load restrictions, no more than 500 mL of clevidipine infusion (formulated in 20% lipid emulsion) was administered in the first 24-h period, and the maximum amount of lipid permitted as part of drug administration was 2.5 g/kg/24 h.
There were no protocol-specified limitations for administering sodium nitroprusside, nitroglycerin or nicardipine and investigators were given freedom to use these drugs as they normally would in clinical practice for treatment of perioperative hypertension. The dose and duration of therapy were recorded. Clevidipine was compared to sodium nitroprusside and nitroglycerin in the preoperative, intraoperative, and postoperative periods. The comparison of clevidipine with nicardipine was restricted to the postoperative period, since nicardipine is not generally used before or during surgery due to its long half-life and potential for higher serum levels in elderly patients or patients with decreased hepatic metabolism. 24 
Study End-Points
The primary end-point of the ECLIPSE trials was safety as assessed by the incidence of death, stroke, myocardial infarction (MI), and renal dysfunction from the initiation of study drug infusion through postoperative day 30. Death was defined as all-cause mortality. Stroke (hemorrhagic or ischemic) was diagnosed by a neurologist based on physical examination and/or brain imaging results. The diagnosis of MI was based on the presence of new 12-lead electrocardiogram changes consistent with myocardial injury and/or cardiac iso-enzyme increases. Renal dysfunction was defined as a postoperative serum creatinine level of Ն2.0 mg/dL (177 mol/L) and an increase in serum creatinine of Ն0.7 mg/dL (62 mol/L) from preoperative baseline, and/or the need for hemodialysis, venovenous filtration, arterial venous filtration, or peritoneal dialysis after surgery. An independent Clinical Events Committee, blinded to treatment, made the final determination as to whether each safety event qualified as a primary end-point based on preestablished criteria uniformly applied to each determination. In addition, CK-MB and serum creatinine laboratory definitions were used as database triggers to identify MI and renal safety end-point events for consideration by the Clinical Events Committee.
The efficacy of clevidipine versus comparator drug for the treatment of acute hypertension was assessed using area under the curve (AUC) analysis of BP excursions beyond predetermined upper and lower limits, normalized per hour (AUC SBP-D ). AUC SBP-D was analyzed as the summation of the integrated SBP-time curve excursions, capturing the product of magnitude (mm Hg) and duration (min) of BP outside the predefined SBP ranges. These ranges, chosen to reflect standard clinical practice and prespecified for analysis purposes, were 65-135 mm Hg intraoperatively (from chest incision through chest closure) and 75-145 mm Hg pre-and postoperatively.
AUC SBP-D was calculated from the BP recorded from the initiation of study drug infusion through either the removal of the arterial line or 24 h after study drug initiation, whichever occurred first. Preoperatively, BP was recorded every 15 min; intraoperatively, every 5 min; and postoperatively every 15 min for 4 h, then once every hour through 24 h (comparison with nitroglycerin or sodium nitroprusside). For the comparison with nicardipine, BP was recorded every 15 min for the first 6 h, then once every hour through 24 h. Hemodynamic data were measured by arterial line and entered into an electronic database.
The total area of the SBP-time curve outside (either above or below) the predefined SBP ranges was calculated ( Fig. 1 ) and normalized per hour (AUC SBP-D ). AUC SBP-D was expressed in units of mm Hg ϫ min/h. In addition, vital signs, clinical laboratory data, fluid administration, the incidence of reflex tachycardia, and serious adverse events (SAEs) including the incidence of atrial fibrillation during study drug administration were also captured. SAEs were recorded up to 30 days postoperatively.
Statistical Analysis
All statistical analyses were performed using the SAS ® system (version 8.2, SAS Institute, Cary, NC) and presented using descriptive statistics. The randomized patient population was defined as all patients who qualified for the study based on prerandomization inclusion and exclusion criteria and were randomized to a treatment group. The modified intentto-treat population was defined as all patients who were randomized into the trial and met postrandomization criteria for perioperative hypertension. The safety population was all randomized patients who received study drug. This report presents safety results based on analysis of the safety population, and efficacy results based on analysis of the modified intent-to-treat population. Data were pooled to provide an overall event rate for clevidipine and comparator arms. Prespecified analysis of each randomized comparison was also performed. P values for the primary end-point analysis were generated using the 2 test. AUC SBP-D was summarized descriptively by treatment group as total area of the SBP-time curve above or below the predefined SBP ranges (65-135 mm Hg intraoperatively, 75-145 mm Hg pre-and postoperatively). Due to asymmetric distribution of AUC, descriptive statistics are presented using range (minimum and maximum), inter-quartile range (first quartile [Q1] and third quartile [Q3]), median (second quartile), mean, and sd. P values for AUC analysis were generated using the Wilcoxon rank sum test, a nonparametric test applicable to asymmetric distributions. The significance level was designated at the two-sided ␣ level of 5%.
To increase our ability to discriminate among treatment groups in the assessment of BP control, we conducted a post hoc analysis in which AUC was calculated as the SBP range was narrowed by incrementally increasing the lower SBP limit by 10 mm Hg, 20 mm Hg, and 30 mm Hg. Additionally, multiple logistic regression analysis was performed to further explore the relationship between the incidence of death and treatment group while controlling for other potential risk factors.
RESULTS
Patients in the ECLIPSE trial were similar with respect to demographics and medical history across all treatment groups (579 received clevidipine or sodium nitroprusside; 546 clevidipine or nitroglycerin, and 381 clevidipine or nicardipine) ( Tables 1 and 2 ). Preexisting chronic hypertension was common in all groups and nearly all patients were receiving antihypertensive medications before surgery. Patient characteristics, demographics, and cardiac surgical procedure groups are detailed in Tables 2 and 3 . In all treatment groups, CABG was the most commonly performed procedure. Off-pump techniques were used in approximately 10%-20% of patients and the number of valve-related procedures was similar among all groups.
The timing of drug administration among treatment groups is presented in Table 4 . In the perioperative clevidipine: nitroglycerin and clevidipine: sodium nitroprusside studies, study drug was primarily initiated during the preoperative or intraoperative period. The majority of patients who initiated antihypertensive treatment pre-or intraoperatively also received therapy in the postoperative setting. Patients in the clevidipine: nicardipine study received the drug postoperatively per protocol as the half-life, volume of distribution, and slow offset of nicardipine was determined to make it less suitable for use in the pre-and intraoperative setting. The median overall infusion duration, total infusion volume, and average infusion rates were greater in the nitroglycerin group compared to patients receiving clevidipine. Overall infusion duration, infusion rates and infusion volumes were comparable between patients receiving clevidipine and sodium nitroprusside. The duration of infusion was similar between clevidipine and nicardipine with the total fluid volume infused and average infusion rate greater for nicardipine compared to clevidipine. The use of adjunctive, alternative antihypertensive drugs was similar among treatment groups. The use of these drugs for the control of hypertension tended to be higher in the sodium nitroprusside-treated group compared with the clevidipine group; with ␤ blockers most commonly administered. There was also an increased tendency for the use of sodium nitroprusside as a second-line antihypertensive drug in patients treated with nitroglycerin compared to those treated with clevidipine (11% vs 2%, respectively).
The primary outcome, 30-day incidence of death, MI, stroke, or renal dysfunction, for all treatment groups is detailed in Table 5 . There was no difference between the pooled clevidipine populations compared with the pooled comparator group for any of the 30-day safety outcome measures. There were no differences in death or adverse outcomes at the time of hospital discharge or Day 7 among groups. Within treatment groups, there were no differences in 30-day outcomes when clevidipine was compared with nitroglycerin and nicardipine. Results for clevidipine compared to sodium nitroprusside were similar as well except for the incidence of 30-day mortality, which was significantly higher in patients who had received sodium nitroprusside compared to clevidipine (4.7% vs 1.7%, P ϭ 0.0445). However, multiple logistic regression analysis for treatment effect (clevidipine vs sodium nitroprusside) as an independent variable in a model that included other risk variables such as surgery duration, AUC SBP-D , age, and medical history, showed no statistically significant association between sodium nitroprusside use and 30-day mortality (odds ratio, 1.968, 95% confidence interval, 0.619 -6.257, P ϭ 0.25). Among 13 patients requiring treatment for hypertension who died in the sodium nitroprusside group, three had hypotension reported as an adverse event.
Comparisons of the pooled data from the entire clevidipine population with the pooled data of the entire comparator group demonstrated that clevidipine was significantly more effective at keeping BP within the prespecified BP range (Table 6, Fig. 2 ). CLV ϭ clevidipine; NTG ϭ nitroglycerin; SNP ϭ sodium nitroprusside; NIC ϭ nicardipine; mITT ϭ modified intent-to-treat. a Two patients in the CLV:NIC treatment group did not receive study medication and were excluded from the safety population. In addition, one patient in the same treatment group was randomized to NIC but received CLV instead. This patient was excluded from the NIC safety population and included in the CLV safety population.
In an analysis of the individual treatment cohorts, clevidipine was significantly more effective at keeping BP within the prespecified range compared with nitroglycerin or sodium nitroprusside (Table 6, Fig. 3 ). The median total AUC SBP-D (representing SBP-time curve excursions outside the prespecified SBP ranges) was significantly lower for patients treated with clevidipine than for patients treated with nitroglycerin (4.14 mm Hg ϫ min/h vs 8.87 mm Hg ϫ min/h; P ϭ 0.0006). In addition, patients treated with nitroglycerin did not meet the target BP range as often compared with clevidipine. The median AUC above the target BP range was significantly lower for clevidipinetreated patients compared to nitroglycerin-treated patients (2.76 mm Hg ϫ min/h vs 7.94 mm Hg ϫ min/h; P ϭ 0.0002). The AUC below the target range was similar between these groups.
For patients treated with clevidipine, the median total AUC was significantly lower compared with patients treated with sodium nitroprusside (4.4 mm Hg ϫ min/h vs 10.5 mm Hg ϫ min/h; P ϭ 0.0027). In addition, patients treated with sodium nitroprusside had significantly greater SBP-time excursions outside the target BP range, both above and below (overshoot) compared to clevidipine. Above the target BP range, median AUC for clevidipine compared with sodium nitroprusside was 2.97 mm Hg ϫ min/hr and 6.61 mm Hg ϫ min/h, respectively (P ϭ 0.031). Below the target BP range, mean AUC for clevidipine compared with sodium nitroprusside was 2.30 mm Data presented as mean Ϯ SD or n (%). CLV ϭ clevidipine; NTG ϭ nitroglycerin; SNP ϭ sodium nitroprusside; NIC ϭ nicardipine; SD ϭ standard deviation; PCI ϭ percutaneous coronary intervention; CABG ϭ coronary artery bypass grafting; CAD ϭ coronary artery disease; ACE ϭ angiotensin-converting enzyme. a Based on n ϭ 263 (CLV), n ϭ 272 (NTG); n ϭ 294 (CLV), n ϭ 279 (SNP); n ϭ 188 (CLV), n ϭ 192 (NIC). b Based on n ϭ 263 (CLV), n ϭ 271 (NTG); n ϭ 294 (CLV), n ϭ 280 (SNP); n ϭ 187 (CLV), n ϭ 192 (NIC).
* P Ͻ 0.05, CLV versus NIC.
Hg ϫ min/h and 8.38 mm Hg ϫ min/h, respectively (P ϭ 0.0006). There were no differences in the median AUC at predetermined target BP ranges of 75-145 mm Hg postoperatively for patients treated with nicardipine compared to clevidipine (Table 6, Fig. 3 ).
When the target BP range was narrowed by raising the lower limit threshold by increments of 10 mm Hg, CLV ϭ clevidipine; NTG ϭ nitroglycerin; SNP ϭ sodium nitroprusside; NIC ϭ nicardipine; Q1 ϭ Quartile 1; Q3 ϭ Quartile 3. a Overall infusion duration starts from the initiation of first infusion to the end of last infusion. b Based on n ϭ 268 (CLV), n ϭ 277 (NTG); n ϭ 296 (CLV), n ϭ 281 (SNP).
there was a direct and progressive increase in the difference of AUC for the pooled comparisons (Fig. 2) as well as each comparator drug when compared to clevidipine (Fig. 3) . When the threshold for the lower BP range was 30 mm Hg higher (i.e., a narrower SBP range of 40 mm Hg), patients treated with clevidipine For each end-point, patients are excluded from the denominator if the last follow-up visit was before 30 days postrandomization and no associated end-point was reported. CLV ϭ clevidipine; NTG ϭ nitroglycerin; SNP ϭ sodium nitroprusside; NIC ϭ nicardipine; CEC ϭ clinical events committee. CLV ϭ clevidipine; NTG ϭ nitroglycerin; SNP ϭ sodium nitroprusside; NIC ϭ nicardipine; AUC SBP-D ϭ area under the SBP-time curve, representing the magnitude and duration of excursions outside of predefined target SBP ranges, normalized per hour. * P ϭ 0.0006, CLV versus NTG. † P ϭ 0.0027, CLV versus SNP. ‡ P ϭ 0.0004, all CLV versus all comparators.
had significantly smaller SBP-time excursions outside of this range than patients treated with nicardipine (77.0 mm Hg ϫ min/h vs 101.6 mm Hg ϫ min/h, P ϭ 0.0231) or sodium nitroprusside (100.2 mm Hg ϫ min/h vs 127.9 mm Hg ϫ min/h, P ϭ 0.0068) (Fig. 3) . The incidence of the most commonly reported adverse events, including atrial fibrillation and sinus tachycardia, were similar for clevidipine and the comparator drugs. Atrial fibrillation was reported as an adverse event at an incidence of 33.6% vs 32.0% (clevidipine versus nitroglycerin); 36.1% vs 32.2% (clevidipine vs sodium nitroprusside); and 35.6% vs 35.2% (clevidipine vs nicardipine), all P ϭ NS. The incidences of SAEs were similar among all groups and are listed in Table 7 . Clinical laboratory data including change in triglyceride levels were similar between clevidipine and the comparator drugs. Clevidipine, which is administered in a lipid emulsion, did not cause an increase in triglyceride levels.
DISCUSSION
In the current study, clevidipine was shown to be as safe as its comparator drugs for the treatment of perioperative hypertension based on a similar frequency in the primary outcome of the 30-day incidence of death, MI, stroke, or renal dysfunction. When individual treatment comparisons were considered, there were no differences in the frequency of this primary outcome between patients receiving clevidipine compared with nitroglycerin, sodium nitroprusside, or nicardipine. We did observe a lower mortality rate, though, for patients treated with clevidipine compared with those receiving sodium nitroprusside, although this difference was only notable as a trend in a multiple logistic regression analysis. Our results further show that clevidipine was a more effective antihypertensive drug based on our analysis of the time and extent SBP was above or below the predefined BP ranges (AUC analysis for BP excursions) than nitroglycerin or sodium nitroprusside at any perioperative SBP range and better than nicardipine when the postoperative SBP range was reduced to 40 mm Hg from the predefined 70 mm Hg (Fig. 3 ). Clevidipine and nicardipine were similar in maintaining BP within the prespecified ranges, but this analysis was limited to the postoperative period based on the protocol design.
Acute perioperative hypertension, first identified as a risk factor for adverse cardiovascular outcome in 1929, 25 is predominantly mediated by an increase in sympathetic activity, resulting in arteriolar vasoconstriction and increased systemic vascular resistance. 26 Although intraoperative hemodynamic abnormalities have been reported to be associated with death, stroke, renal dysfunction, perioperative MI, and increased mortality, these studies often used a small sample size and lacked statistical power, were retrospective and included discontinuous data, included methods specific to certain patient populations and/or surgical procedures, and were not analyzed to determine specific target BP thresholds. [27] [28] [29] [30] Therefore, they provide limited information on the impact of perioperative hypertension management on patient outcomes. An association between hypertension and postoperative surgical bleeding has also been demonstrated. 31 In part because of these strong associations, and because of other practical safety concerns related to the hydraulic pressure and aortovascular stressstrain modulation requirements during cardiac surgery with cardiopulmonary bypass (e.g., cannulation and decannulation), and the requirements of the postoperative period for weaning from mechanical ventilation and analgesia, manipulation and control of BP is commonly used during cardiac surgery.
Currently, nitroglycerin and sodium nitroprusside are commonly used during cardiac surgery to control BP; however, both have significant limitations. Nitroglycerin is a relatively weak arteriolar vasodilator with a primary effect on dilating venous capacitance vessels to reduce preload. Sodium nitroprusside also produces significant venodilation and causes reflex tachycardia, as well as inhibition of hypoxic pulmonary vasoconstriction, increase in intracranial pressure, and a redistribution of blood flow away from vital end-organs 1,2 including the kidney 32 and gastrointestinal tract. The use of sodium nitroprusside also is associated with systemic cyanide toxicity, a risk that may be accelerated during cardiac surgery requiring cardiopulmonary bypass. 33 Sodium nitroprusside may be difficult to titrate and is recognized to cause unwanted ("overshoot") hypotension and hypertension. In a study comparing sodium nitroprusside with nicardipine, patients treated with sodium nitroprusside needed more time to reach target BP goals and required more dose adjustments. The venodilatory effects of sodium nitroprusside may produce unpredictable swings in BP in patients with diastolic dysfunction or hypovolemia. 34 Nicardipine, a dihydropyridine calcium channel blocker, may be limited for use in the acute preoperative and intraoperative setting because of its long half-life, slower offset of action, and potential for increased serum levels in elderly patients or patients with altered hepatic function. 24 Additionally, bolus doses of nicardipine, after IV infusion, appear to be needed to obtain the rapid onset of action seen with other vasodilator drugs like sodium nitroprusside. Clevidipine is a third-generation dihydropyridine calcium channel blocker, specifically designed for treatment of acute hypertension, with a rapid onset and offset of action. The characteristic of fast offset and onset is due to an easily hydrolyzable ester group in the clevidipine molecular structure 22 which is rapidly metabolized by esterases in the blood and vascular tissues upon IV administration. The resulting ultrashort half-life of approximately 1 min 20 -22 makes clevidipine an attractive drug for patients who need rapid BP adjustments over time.
Implications for these data may become important as the selection of drugs to more narrowly control acute hypertension in the surgical and critical care setting is further investigated and guidelines are defined. This is also important because preexisting hypertension, especially among the elderly surgical population, is present in more than two-thirds of all patients Ն60 yr, 9 with upwards of 90% prevalence in cardiac surgery, 35 and has been identified as an important risk factor for adverse outcome. 4, 35 Limitations of the study include the open-label design. However, adjudication of study end-points by an independent Clinical Events Committee was used to minimize any potential bias. Additionally, by protocol, clevidipine was dosed in a standard fashion at all study sites, whereas comparator drugs were administered according to institutional practice. This limitation enabled a real-world analysis that was more applicable to actual clinical practice.
The use of adjunctive, alternative antihypertensive drugs was similar between groups. Patients who received nitroglycerin received more second-line sodium nitroprusside administration for the control of hypertension, suggesting that nitroglycerin, in addition to the increased AUC above the target SBP limit, is an ineffective antihypertensive drug in cardiac surgical patients. An important and consistent finding from all three studies with clevidipine was that the BP results after treatment with clevidipine were remarkably similar, indicating that predictable BP control can be achieved with clevidipine throughout the operative setting.
The primary purpose of this study was to evaluate the safety of clevidipine compared with other commonly used antihypertensive drugs in patients undergoing cardiac surgery. Although the composite safety end-point of 30-day death, MI, stroke, or renal dysfunction was similar among the treatment groups, we did find that patients treated with clevidipine had a lower mortality rate than those treated with sodium nitroprusside. It is possible that these observations were due to confounding factors among the treatment groups not considered in our analysis. Indeed, the number of patients undergoing higher-risk combined CABG and cardiac valve surgery was higher in the sodium nitroprusside group compared with the clevidipine group, although this difference was not statistically significant (primary and repeat combination CABG and valve surgery for clevidipine versus sodium nitroprusside: P ϭ 0.18). In addition, the small number of observed events in this analysis may have led to a type I error. Regardless, whether the drug choice for treating perioperative hypertension can modify risk for mortality after cardiac surgery requires further prospective study. 
